Xenobiotica最新文献_第5页

Preface for special issue: "Emerging strategies, technologies, and approaches for the next generation ADCs". 特刊序言："下一代 ADC 的新兴战略、技术和方法"。

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-08-01 Epub Date: 2024-09-27 DOI: 10.1080/00498254.2024.2386407

Markus Walles, Keyang Xu

{"title":"Preface for special issue: \"Emerging strategies, technologies, and approaches for the next generation ADCs\".","authors":"Markus Walles, Keyang Xu","doi":"10.1080/00498254.2024.2386407","DOIUrl":"10.1080/00498254.2024.2386407","url":null,"abstract":"1. Antibody-drug conjugates (ADCs) represent an advanced category of biotherapeutic agents, typically consisting of an antibody bound to a biologically-active cytotoxic agent. Since the first ADC, MylotargTM, was approved in 2000, there have been fifteen ADCs sanctioned to date, with thirteen receiving approval from the FDA for the treatment of a variety of cancers, including blood malignancies and solid tumors.2. In this Special Issue of Xenobiotica focusing on ADCs, our goal is to compile a collection of papers, featuring both original research and review articles authored by specialists in academia and the pharmaceutical industry, to showcase some of the historical insights gained, current progress, and future prospects to enhance comprehension and tackle obstacles in the field of ADC development for cancer therapy.3. This special issue features articles that evaluate key components of ADC development, including payload design, innovative linker chemistries, and the use of new technologies for site-specific conjugations beyond traditional engineered cysteines. It also spotlights cutting-edge ADC structures like bispecific ADCs, dual-payload ADCs, targeted nanoparticles and antibody oligonucleotide conjugates (AOCs).4. Several other papers discuss bioanalytical and ADME strategies for ADCs as well. In addition, approaches to improve the translation of pharmacokinetics, safety, and therapeutic index (TI) of ADCs are presented.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"439-441"},"PeriodicalIF":1.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting routes of phase I and II metabolism based on quantum mechanics and machine learning. 基于量子力学和机器学习的第一阶段和第二阶段代谢路径预测。

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-07-01 Epub Date: 2024-08-21 DOI: 10.1080/00498254.2023.2284251

Mario Öeren, Peter A Hunt, Charlotte E Wharrick, Hamed Tabatabaei Ghomi, Matthew D Segall

{"title":"Predicting routes of phase I and II metabolism based on quantum mechanics and machine learning.","authors":"Mario Öeren, Peter A Hunt, Charlotte E Wharrick, Hamed Tabatabaei Ghomi, Matthew D Segall","doi":"10.1080/00498254.2023.2284251","DOIUrl":"10.1080/00498254.2023.2284251","url":null,"abstract":"Unexpected metabolism could lead to the failure of many late-stage drug candidates or even the withdrawal of approved drugs. Thus, it is critical to predict and study the dominant routes of metabolism in the early stages of research.We describe the development and validation of a 'WhichEnzyme' model that accurately predicts the enzyme families most likely to be responsible for a drug-like molecule's metabolism. Furthermore, we combine this model with our previously published regioselectivity models for Cytochromes P450, Aldehyde Oxidases, Flavin-containing Monooxygenases, UDP-glucuronosyltransferases and Sulfotransferases - the most important Phase I and Phase II drug metabolising enzymes - and a 'WhichP450' model that predicts the Cytochrome P450 isoform(s) responsible for a compound's metabolism.The regioselectivity models are based on a mechanistic understanding of these enzymes' actions and use quantum mechanical simulations with machine learning methods to accurately predict sites of metabolism and the resulting metabolites. We train heuristics based on the outputs of the 'WhichEnzyme', 'WhichP450', and regioselectivity models to determine the most likely routes of metabolism and metabolites to be observed experimentally.Finally, we demonstrate that this combination delivers high sensitivity in identifying experimentally reported metabolites and higher precision than other methods for predicting in vivo metabolite profiles.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"379-393"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107592386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of quantitative pharmacology analysis to support early clinical development of oncology drugs: dose selection. 应用定量药理学分析支持肿瘤药物的早期临床开发：剂量选择。

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-07-01 Epub Date: 2024-08-21 DOI: 10.1080/00498254.2024.2377577

Ningyuan Zhang, Yu Li, Wenbin Cui, Xiangqing Yu, Ying Huang

{"title":"Application of quantitative pharmacology analysis to support early clinical development of oncology drugs: dose selection.","authors":"Ningyuan Zhang, Yu Li, Wenbin Cui, Xiangqing Yu, Ying Huang","doi":"10.1080/00498254.2024.2377577","DOIUrl":"10.1080/00498254.2024.2377577","url":null,"abstract":"The selection of appropriate starting dose and suitable method to predict an efficacious dose for novel oncology drug in the early clinical development stage poses significant challenges. The traditional methods of using body surface area transformation from toxicology studies to predict the first-in human (FIH) starting dose, or simply selecting the maximum tolerated dose (MTD) or maximum administered dose (MAD) as efficacious dose or recommended phase 2 dose (RP2D), are usually inadequate and risky for novel oncology drugs.Due to the regulatory efforts aimed at improving dose optimisation in oncology drug development, clinical dose selection is now shifting away from these traditional methods towards a comprehensive benefit/risk assessment-based approach. Quantitative pharmacology analysis (QPA) plays a crucial role in this new paradigm. This mini-review summarises the use of QPA in selecting the starting dose for oncology FIH studies and potential efficacious doses for expansion or phase 2 trials. QPA allows for a more rational and scientifically based approach to dose selection by integrating information across studies and development phases.In conclusion, the application of QPA in oncology drug development has the potential to significantly enhance the success rates of clinical trials and ultimately support clinical decision-making, particularly in dose selection.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"420-423"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediction of the liver safety profile of a first-in-class myeloperoxidase inhibitor using quantitative systems toxicology modeling. 利用定量系统毒理学模型预测第一类髓过氧化物酶抑制剂的肝脏安全性特征

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-07-01 Epub Date: 2024-08-21 DOI: 10.1080/00498254.2024.2361027

Jeffrey L Woodhead, Yeshi Gebremichael, Joyce Macwan, Irfan A Qureshi, Richard Bertz, Victoria Wirtz, Brett A Howell

{"title":"Prediction of the liver safety profile of a first-in-class myeloperoxidase inhibitor using quantitative systems toxicology modeling.","authors":"Jeffrey L Woodhead, Yeshi Gebremichael, Joyce Macwan, Irfan A Qureshi, Richard Bertz, Victoria Wirtz, Brett A Howell","doi":"10.1080/00498254.2024.2361027","DOIUrl":"10.1080/00498254.2024.2361027","url":null,"abstract":"The novel myeloperoxidase inhibitor verdiperstat was developed as a treatment for neuroinflammatory and neurodegenerative diseases. During development, a computational prediction of verdiperstat liver safety was performed using DILIsym v8A, a quantitative systems toxicology (QST) model of liver safety.A physiologically-based pharmacokinetic (PBPK) model of verdiperstat was constructed in GastroPlus 9.8, and outputs for liver and plasma time courses of verdiperstat were input into DILIsym. In vitro experiments measured the likelihood that verdiperstat would inhibit mitochondrial function, inhibit bile acid transporters, and generate reactive oxygen species (ROS); these results were used as inputs into DILIsym, with two alternate sets of parameters used in order to fully explore the sensitivity of model predictions. Verdiperstat dosing protocols up to 600 mg BID were simulated for up to 48 weeks using a simulated population (SimPops) in DILIsym.Verdiperstat was predicted to be safe, with only very rare, mild liver enzyme increases as a potential possibility in highly sensitive individuals. Subsequent Phase 3 clinical trials found that ALT elevations in the verdiperstat treatment group were generally similar to those in the placebo group. This validates the DILIsym simulation results and demonstrates the power of QST modelling to predict the liver safety profile of novel therapeutics.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"401-410"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xenobiotica Special Edition Preface. Xenobiotica 特别版序言。

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-07-01 Epub Date: 2024-08-21 DOI: 10.1080/00498254.2024.2372825

Alan G E Wilson

引用次数: 0

The history and future of population pharmacokinetic analysis in drug development. 药物开发中群体药代动力学分析的历史与未来。

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-07-01 Epub Date: 2024-08-21 DOI: 10.1080/00498254.2023.2291792

Nathan Teuscher

{"title":"The history and future of population pharmacokinetic analysis in drug development.","authors":"Nathan Teuscher","doi":"10.1080/00498254.2023.2291792","DOIUrl":"10.1080/00498254.2023.2291792","url":null,"abstract":"The analysis of pharmacokinetic data has been in a constant state of evolution since the introduction of the term pharmacokinetics. Early work focused on mechanistic understanding of the absorption, distribution, metabolism and excretion of drug products.The introduction of non-linear mixed effects models to perform population pharmacokinetic analysis initiated a paradigm shift. The application of these models represented a major shift in evaluating variability in pharmacokinetic parameters across a population of subjects.While technological advancements in computing power have fueled the growth of population pharmacokinetics in drug development efforts, there remain many challenges in reducing the time required to incorporate these learnings into a model-informed development process. These challenges exist because of expanding datasets, increased number of diagnostics, and more complex mathematical models.New machine learning tools may be potential solutions for these challenges. These new methodologies include genetic algorithms for model selection, machine learning algorithms for covariate selection, and deep learning models for pharmacokinetic and pharmacodynamic data. These new methods promise the potential for less bias, faster analysis times, and the ability to integrate more data.While questions remain regarding the ability of these models to extrapolate accurately, continued research in this area is expected to address these questions.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"394-400"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138488579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics of intranasal drugs, still a missed opportunity? 鼻内用药的药代动力学，还在错失良机吗？

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-07-01 Epub Date: 2024-08-21 DOI: 10.1080/00498254.2024.2349046

Maria Luisa Sardu, Italo Poggesi

{"title":"Pharmacokinetics of intranasal drugs, still a missed opportunity?","authors":"Maria Luisa Sardu, Italo Poggesi","doi":"10.1080/00498254.2024.2349046","DOIUrl":"10.1080/00498254.2024.2349046","url":null,"abstract":"The intranasal (IN) route of administration is important for topical drugs and drugs intended to act systemically. More recently, direct nose-to-brain input was considered to bypass the blood-brain barrier.Processes related to IN absorption and nose-to-brain distribution are complex and depend, sometimes in contrasting ways, on chemico-physical and structural parameters of the compounds, and on formulation options.Due to the intricacies of these processes and despite the large number of articles published on many different IN compounds, it appears that absorption after IN dosing is not yet fully understood. In particular, at variance of the understanding and modelling approaches that are available for predicting the pharmacokinetics (PK) following oral administration of xenobiotics, it appears that there is not a similar understanding of the chemico-physical and structural determinants influencing drug absorption and disposition of compounds after IN administration, which represents a missed opportunity for this research field. This is even more true regarding the understanding of the direct nose-to-brain input. Due to this, IN administrations may represent an interesting and open research field for scientists aiming to develop PK property predictions tools, mechanistic PK models describing rate and extent of IN absorption, and translational tools to anticipate the clinical PK following IN dosing based on in vitro and in vivo non clinical experiments.This review intends to provide: i) some basic knowledge related to the physiology of PK after IN dosing, ii) a non-exhaustive list of preclinical and clinical examples related to compounds explored for the potential nose-to-blood and nose-to-brain passage, and iii) the identification of some areas requiring improvements, the understanding of which may facilitate the development of IN drug candidates.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"424-438"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perspectives on the use of machine learning for ADME prediction at AstraZeneca. 阿斯利康将机器学习用于 ADME 预测的观点。

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-07-01 Epub Date: 2024-08-21 DOI: 10.1080/00498254.2024.2352598

Erik Gawehn, Nigel Greene, Filip Miljković, Olga Obrezanova, Vigneshwari Subramanian, Maria-Anna Trapotsi, Susanne Winiwarter

{"title":"Perspectives on the use of machine learning for ADME prediction at AstraZeneca.","authors":"Erik Gawehn, Nigel Greene, Filip Miljković, Olga Obrezanova, Vigneshwari Subramanian, Maria-Anna Trapotsi, Susanne Winiwarter","doi":"10.1080/00498254.2024.2352598","DOIUrl":"https://doi.org/10.1080/00498254.2024.2352598","url":null,"abstract":"A drug's pharmacokinetic (PK) profile will determine its dose and the frequency of administration as well as the likelihood of observing any adverse drug reactions.It is important to understand these PK properties as early as possible in the drug discovery process, ideally, to accurately predict these prior to synthesising the molecule leading to significant improvements in efficiency.In this paper, we describe the approaches used within AstraZeneca to improve our ability of predicting the preclinical and human pharmacokinetic profiles of novel molecules using machine learning and artificial intelligence.We will show how combining chemical structure-based approaches with experimentally derived properties enables improved predictions of in vivo pharmacokinetics and can be extended to molecules that go beyond the classical Lipinski's rule-of-five space.We will also discuss how combining these in vitro and in vivo predictive models could ultimately improve our ability to predict the human outcome at the point of chemical design.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":"54 7","pages":"368-378"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury. 人类细胞色素 P450 抑制数据在评估药物引起的肝损伤中的实用性。

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-07-01 Epub Date: 2024-08-21 DOI: 10.1080/00498254.2024.2312505

Shunnosuke Kaito, Jun-Ichi Takeshita, Misaki Iwata, Takamitsu Sasaki, Takuomi Hosaka, Ryota Shizu, Kouichi Yoshinari

{"title":"Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury.","authors":"Shunnosuke Kaito, Jun-Ichi Takeshita, Misaki Iwata, Takamitsu Sasaki, Takuomi Hosaka, Ryota Shizu, Kouichi Yoshinari","doi":"10.1080/00498254.2024.2312505","DOIUrl":"10.1080/00498254.2024.2312505","url":null,"abstract":"Drug-induced liver injury (DILI) is a major cause of drug development discontinuation and drug withdrawal from the market, but there are no golden standard methods for DILI risk evaluation. Since we had found the association between DILI and CYP1A1 or CYP1B1 inhibition, we further evaluated the utility of cytochrome P450 (P450) inhibition assay data for DILI risk evaluation using decision tree analysis.The inhibitory activity of drugs with DILI concern (DILI drugs) and no DILI concern (no-DILI drugs) against 10 human P450s was assessed using recombinant enzymes and luminescent substrates. The drugs were also subjected to cytotoxicity assays and high-content analysis using HepG2 cells. Molecular descriptors were calculated by alvaDesc.Decision tree analysis was performed with the data obtained as variables with or without P450-inhibitory activity to discriminate between DILI drugs and no-DILI drugs. The accuracy was significantly higher when P450-inhibitory activity was included. After the decision tree discrimination, the drugs were further discriminated with the P450-inhibitory activity. The results demonstrated that many false-positive and false-negative drugs were correctly discriminated by using the P450 inhibition data.These results suggest that P450 inhibition assay data are useful for DILI risk evaluation.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"411-419"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139692988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In silico ADME/tox comes of age: twenty years later. 硅学 ADME/tox 时代的到来：二十年后。

IF 1.3 4区医学

Xenobiotica Pub Date : 2024-07-01 Epub Date: 2023-08-08 DOI: 10.1080/00498254.2023.2245049

Sean Ekins, Thomas R Lane, Fabio Urbina, Ana C Puhl

{"title":"In silico ADME/tox comes of age: twenty years later.","authors":"Sean Ekins, Thomas R Lane, Fabio Urbina, Ana C Puhl","doi":"10.1080/00498254.2023.2245049","DOIUrl":"10.1080/00498254.2023.2245049","url":null,"abstract":"In the early 2000s pharmaceutical drug discovery was beginning to use computational approaches for absorption, distribution, metabolism, excretion and toxicity (ADME/Tox, also known as ADMET) prediction. This emphasis on prediction was an effort to reduce the risk of later stage failures from ADME/Tox.Much has been written in the intervening twenty plus years and significant expenditure has occurred in companies developing these in silico capabilities which can be gleaned from publications. It is therefore an appropriate time to briefly reflect on what was proposed then and what the reality is today.20 years ago, we tended to optimise bioactivity and perhaps one ADME/Tox property at a time. Previously pharmaceutical companies needed a whole infrastructure for models - in silico and in vitro experts, IT, champions on a project team, educators and management support. Now we are in the age of generative de novo design where bioactivity and many ADME/Tox properties can be optimised and large language model technologies are available.There are also some challenges such as the focus on very large molecules which may be outside of current ADME/Tox models.We provide an opportunity to look forward with the increasing public data for ADME/Tox as well as expanded types of algorithms available.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"352-358"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10850432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10331199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0